Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.

Emi Kawada-Horitani Shunbun KitaTomonori OkitaYuto NakamuraHiroyuki NishidaYoichi HonmaShiro FukudaYuri Tsugawa-ShimizuJunji KozawaTakaaki SakaueYusuke KawachiYuya FujishimaHitoshi NishizawaMiyuki AzumaNorikazu MaedaIichiro Shimomura

Published in: Diabetologia (2022)

Our results suggest that MSCs can prevent the incidence of diabetes associated with immune checkpoint cancer therapy and may be worth further consideration for new adjuvant cell therapy.

Keyphrases

cell therapy
mesenchymal stem cells
type diabetes
cancer therapy
umbilical cord
glycemic control
endothelial cells
cardiovascular disease
bone marrow
drug delivery
early stage
stem cells
risk factors
induced pluripotent stem cells
pluripotent stem cells
insulin resistance
skeletal muscle